Buy-and-Bill Economics for Gastroenterology Infusion
Buy-and-bill gives GI practices greater control over infusion care while exposing them to inventory costs, reimbursement delays, and payer changes. Sustainable programs depend on aligning pharmaceutical purchasing, actual collections, and the full cost of delivering treatment.
A gastroenterology practice may purchase thousands of dollars in biologic inventory before a patient ever sits down for an infusion. The medication is ordered, paid for by the practice, stored appropriately, administered to the patient, billed to the health plan, and then reimbursed later. If acquisition cost and reimbursement remain aligned, that process can support a sustainable in-office infusion program. If they do not, the financial exposure can add up quickly.
That is the basic economic tension behind buy-and-bill.
For gastroenterology practices treating inflammatory bowel disease and other conditions with provider-administered specialty medications, buy-and-bill connects pharmaceutical purchasing directly to reimbursement. Decisions involving GPO pricing, distributor contracts, payer policies, biosimilar formularies, inventory levels, and reimbursement rates can all influence whether administering a particular drug makes financial sense.
Understanding those economics is especially important as GI practices navigate a market with more biosimilars, specialty pharmacy mandates, changing payer preferences, and growing pressure to control specialty drug spending.
What Is Buy-and-Bill in Gastroenterology?
Under the buy-and-bill model, a gastroenterology practice purchases a provider-administered drug through a pharmaceutical distributor or other approved purchasing channel.
The practice then maintains the medication in inventory, administers it to an eligible patient, and bills the patient’s insurer for the drug and the administration service.
CMS explains through its Medicare Part B drug guidance that many Part B-covered drugs are infused or injected by physicians, including therapies used by gastroenterologists and other specialists. Medicare generally makes a payment for the covered drug and a separate payment for administering it.
At a simplified level, the process looks like this:
- The practice verifies coverage and authorization
- The medication is purchased
- The practice pays the acquisition cost
- The medication enters practice inventory
- The patient receives the infusion
- The practice submits a claim
- The payer reimburses the covered drug and administration services
The difference between what the practice pays to acquire the medication and what the payer ultimately reimburses is one of the central economic considerations within buy-and-bill.
Why Buy-and-Bill Matters to GI Infusion Practices
Buy-and-bill gives gastroenterology practices direct control over a major part of the infusion process.
Instead of relying on an outside specialty pharmacy to obtain a patient-specific dose, the practice can maintain inventory based on expected utilization and schedule eligible patients around products it already has available.
That control can support:
- More predictable inventory availability
- Greater scheduling flexibility
- Direct pharmaceutical purchasing
- Access to applicable GPO contracts
- Greater visibility into acquisition costs
- Centralized medication handling
- Faster response when appointments change
Buy-and-bill also has financial significance for independent practices. Avalere Health analyzed Medicare claims across several specialties and found that revenue associated with acquiring and administering Part B drugs can represent a meaningful part of physician practice economics, including for gastroenterology. Its analysis of buy-and-bill in physician practices notes that a practice’s ability to finance high-cost specialty drug inventory is one factor influencing its participation in the model.
That financial role is important because an infusion program has costs that extend well beyond medication acquisition.
The Economics Begin With Acquisition Cost
Before a practice can evaluate reimbursement, it needs to understand what the medication actually costs to purchase.
The acquisition price may be influenced by:
- Pharmaceutical manufacturer contracts
- GPO pricing
- Distributor pricing
- Product volume
- Biosimilar availability
- Direct agreements
- Contract eligibility
- Class of trade
- Product-specific programs
A gastroenterology practice participating in an infusion GPO may qualify for contract pricing established between the GPO and pharmaceutical manufacturer.
That does not mean every member automatically receives the same price for every medication. Eligibility can depend on the individual contract, provider classification, class of trade, and other manufacturer requirements.
For practice administrators, this makes specialty drug purchasing an ongoing process rather than a one-time contracting decision.
A change in GPO pricing, manufacturer terms, or product mix can alter the economics of a medication even before payer reimbursement changes.
Reimbursement Is the Other Half of the Equation
The practice then needs to understand how the payer reimburses the medication.
Medicare provides one of the clearest examples. CMS states in its current Average Sales Price guidance that most separately payable Medicare Part B drugs and biological products have a payment limit based on Average Sales Price, or ASP, plus 6 percent. CMS receives ASP data from manufacturers and updates Medicare payment limits quarterly.
Commercial insurance does not necessarily follow the exact same reimbursement methodology.
A GI practice may therefore have several reimbursement arrangements for the same medication depending on the patient’s coverage.
That creates questions such as:
- How much does the practice pay for this product?
- What will Medicare reimburse?
- What will each commercial payer reimburse?
- Does reimbursement differ by biosimilar?
- Is there a separate administration payment?
- How quickly will the payer process the claim?
- Is patient coinsurance part of the expected payment?
- What happens if the claim is denied?
The economics cannot be evaluated using acquisition cost alone.
A lower purchase price is only beneficial if the reimbursement model and actual collections make the therapy financially sustainable.

Drug Margin Is Not the Same as Profit
The difference between drug acquisition cost and drug reimbursement is sometimes described as the drug margin.
That margin should not be confused with pure practice profit.
An infusion program carries significant operating expenses, including:
- Infusion nurses
- Clinical oversight
- Infusion chairs and equipment
- Medication storage
- Benefits verification
- Prior authorization staff
- Scheduling
- Billing and collections
- Supplies
- Emergency preparedness
- Pharmacy and inventory management
- Facility overhead
The economics of buy-and-bill therefore involve more than whether the payer reimburses slightly more than the acquisition cost.
Practices need enough financial capacity to support the infrastructure required to safely administer specialty medications and manage the administrative work surrounding them.
This is particularly relevant for community GI practices that maintain their own infusion suites rather than referring all provider-administered treatment to hospitals or outside infusion centers.
Working Capital Is a Major Consideration
Buy-and-bill requires practices to spend money before they receive reimbursement.
That creates a working-capital requirement.
If a practice purchases a high-cost biologic today and does not receive payment for several weeks, the practice carries that expense during the time between acquisition and reimbursement.
Multiply that across a large IBD infusion population and the amount of capital tied up in pharmaceutical inventory and unpaid claims can become substantial.
Practices therefore need to think about:
- Inventory value
- Payment timing
- Accounts receivable
- Claim denial rates
- Expected patient volume
- Purchasing terms
- Cash reserves
- Product utilization
A practice may have favorable contract pricing and reimbursement but still experience cash-flow pressure if large amounts of money are continually tied up in inventory and outstanding claims.
That makes revenue-cycle management an important part of buy-and-bill economics.

Inventory Has Financial Risk Too
Owning the medication gives the practice flexibility, but it also means assuming inventory risk.
A practice may purchase a product based on expected patient demand only to experience:
- A payer formulary change
- A biosimilar switch
- A treatment discontinuation
- A patient changing insurance
- Reduced utilization
- Product expiration
- A manufacturer contract change
- A reimbursement reduction
The more products a practice needs to maintain, the more complicated inventory planning becomes.
This is particularly relevant in IBD because the number of biologics and biosimilars available continues to grow. The American Gastroenterological Association’s current IBD Drug Guide includes dozens of potential treatment options across oral, injectable, and infusion routes, demonstrating just how broad the modern IBD treatment environment has become.
A GI practice may therefore need to balance enough inventory to avoid treatment delays against the financial risk of carrying more product than it can realistically use.
Biosimilars Are Changing Buy-and-Bill Calculations
Biosimilars have introduced additional competition into the market for biologic therapies used in IBD.
That can create lower acquisition opportunities, but it can also make purchasing and reimbursement more complicated.
A payer may prefer one infliximab biosimilar while another insurer prefers a different product. The practice may have favorable GPO pricing on one biosimilar but less favorable economics on another.
There have also been cases where GI practices report reimbursement falling below acquisition cost.
The American Gastroenterological Association has warned through its biosimilar reimbursement advocacy resources that some GI practices have experienced situations where payer reimbursement for preferred biologic products does not match what the practice pays to acquire them. AGA has advocated for reimbursement of preferred products to reflect provider acquisition costs.
When reimbursement falls below acquisition cost, the practice may lose money before even accounting for the cost of running the infusion center.
That creates an obvious sustainability problem.
GPO Pricing Can Influence the Acquisition Side
A specialty healthcare GPO cannot control payer reimbursement, but GPO pricing can influence the other side of the economic equation.
For qualifying providers, GPO contracts may provide access to pharmaceutical contract pricing established with participating manufacturers.
That can help practices better understand what they will pay for a specialty medication and identify purchasing programs relevant to their organization.
A GI practice evaluating its buy-and-bill economics may therefore consider:
- Current distributor price
- Available GPO pricing
- Manufacturer contract terms
- Direct agreements
- Contract effective dates
- Product-specific rebates
- Provider eligibility
- Class of trade requirements
Small differences in acquisition cost can become meaningful when multiplied across recurring infusions and a large patient population.
This is one reason specialty drug purchasing should be reviewed alongside payer reimbursement rather than treated as a separate administrative function.

Class of Trade Can Affect Contract Eligibility
Pharmaceutical class of trade identifies the type of organization participating in the pharmaceutical purchasing environment.
A physician-based gastroenterology infusion practice, hospital outpatient department, independent infusion center, and specialty pharmacy may all acquire or administer the same medication, but manufacturers may classify those organizations differently.
That classification can affect eligibility for certain pharmaceutical GPO contracts and pricing programs.
Accurate class of trade becomes particularly important for organizations operating multiple types of healthcare businesses.
For example, a healthcare organization might operate:
- Gastroenterology physician practices
- In-office infusion suites
- Ambulatory infusion centers
- Specialty pharmacy operations
Those entities may not necessarily qualify for identical manufacturer programs.
Accurate provider classification and roster management help ensure that the correct purchasing arrangements are applied to the appropriate locations.
Buy-and-Bill Also Gives Practices More Control Over Scheduling
The economics of buy-and-bill are closely connected to operational flexibility.
When the practice owns medication inventory, an authorized patient can often be scheduled around product already available onsite.
If one patient needs to postpone an infusion, the practice may have greater flexibility to use appropriate inventory elsewhere, subject to product requirements and clinical circumstances.
That can be different from patient-specific specialty pharmacy acquisition.
Under white bagging, a specialty pharmacy dispenses medication for a specific patient and ships it to the provider for administration. The National Infusion Center Association’s white bagging resources explain that this model bypasses the traditional buy-and-bill process and reduces the provider’s control over drug inventory.
The economic impact and the operational impact are therefore connected.
The practice may lose the pharmaceutical purchasing component while still remaining responsible for storing, administering, and clinically managing the therapy.
White Bagging Can Change Infusion Economics
Payer-mandated specialty pharmacy acquisition is one of the clearest challenges to the traditional buy-and-bill model.
Instead of the gastroenterology practice purchasing the drug:
- A designated specialty pharmacy acquires or dispenses the medication.
- The specialty pharmacy ships a patient-specific dose to the infusion location.
- The gastroenterology practice administers the medication.
- The specialty pharmacy or associated entity bills for the drug.
- The GI practice generally bills for the administration service.
That means the practice no longer participates in the drug acquisition and reimbursement economics for that patient.
Avalere’s research on infusion care and white bagging found that health plans and PBMs have increasingly required medications previously purchased directly by practices to instead be supplied through specialty pharmacies, creating both administrative and economic effects for infusion providers.
For GI practices, the significance can extend beyond lost drug margin.
The practice may still maintain the staff, chairs, supplies, storage, and clinical infrastructure necessary to deliver treatment.
That raises a broader question about how physician-based infusion remains financially sustainable when the purchasing component is removed.
Payer Mix Can Significantly Affect Performance
Two GI practices administering similar medications to similar numbers of patients can have very different financial results depending on payer mix.
A practice with a larger Medicare population may experience one reimbursement structure, while practices with different commercial contracts may face very different payment rates and authorization requirements.
Practices should therefore avoid evaluating buy-and-bill economics solely at the product level.
The same medication can produce different financial results depending on:
- Payer
- Contract
- Patient benefit design
- Reimbursement methodology
- Acquisition channel
- Authorization requirements
- Collection rate
Tracking profitability only in aggregate can hide products or payer relationships that are consistently underperforming.
A more useful analysis looks at the relationship between product, acquisition cost, payer, reimbursement, and actual collections.
Claim Denials Can Turn Expected Margin Into Loss
The financial model also assumes that the practice gets paid.
A medication may appear economically viable based on expected reimbursement, but a denied or underpaid claim changes that calculation considerably.
Common issues can include:
- Missing authorization
- Incorrect coding
- Coverage changes
- Incorrect units
- Payer-specific billing requirements
- Patient eligibility changes
- Medical necessity documentation
- Coordination-of-benefits issues
When a high-cost medication is involved, even a small number of unresolved claims can represent significant accounts receivable.
That makes benefits verification and authorization part of the financial process, not simply administrative prerequisites.
AGA maintains reimbursement and coverage resources for GI practices that include Medicare payment education, coding information, prior authorization tools, and payer-navigation guidance.
Strong revenue-cycle controls can help reduce the risk of a practice purchasing and administering medication without a clear path to payment.
Medicare ASP Changes Should Be Monitored Quarterly
Practices treating Medicare beneficiaries need to monitor changes in Part B drug payment limits.
CMS publishes updated Medicare Part B Drug Payment Limit Files each quarter, reflecting current ASP-based payment limits for covered products.
A product that was financially favorable under one quarter’s acquisition and reimbursement relationship may not remain identical indefinitely.
Practices may therefore want to review:
- New ASP files
- Distributor acquisition costs
- GPO contract pricing
- Utilization
- Biosimilar changes
- Payer reimbursement updates
The same principle applies to commercial payers, even though their reimbursement methodologies may differ.
Buy-and-bill economics should be monitored continuously rather than evaluated once when the product first enters the practice.
What Makes a Sustainable GI Infusion Program?
There is no single margin or financial formula that works for every gastroenterology practice.
A sustainable program generally requires alignment across several areas:
- Appropriate patient volume
- Reliable prior authorization
- Competitive pharmaceutical purchasing
- Favorable or sustainable GPO pricing
- Predictable reimbursement
- Efficient inventory management
- Strong billing and collections
- Appropriate staffing
- Manageable overhead
- Product availability
- Accurate payer information
Practices also need enough flexibility to respond when those conditions change.
A payer may add a specialty pharmacy requirement. A new biosimilar may become preferred. Contract pricing may change. CMS may publish a new ASP payment amount. Patient utilization may shift.
A financially healthy infusion operation needs systems capable of detecting and responding to those changes before they create significant losses.
What Pharmaceutical Manufacturers Should Understand
Buy-and-bill economics also matter to manufacturers.
A manufacturer can secure FDA approval, formulary coverage, and physician interest and still encounter adoption barriers if community providers cannot sustainably acquire and administer the product.
Manufacturers serving physician-based infusion markets should pay attention to:
- Provider acquisition costs
- GPO contract pricing
- Reimbursement trends
- Distributor availability
- Payer preferences
- Biosimilar competition
- Specialty pharmacy mandates
- Alternative site-of-care utilization
- Provider feedback
The American Gastroenterological Association’s advocacy around “underwater” biosimilars demonstrates why provider economics can directly affect product access. AGA has reported that some practices have had to stop administering certain products when reimbursement did not cover acquisition cost.
For manufacturers, that means provider economics are part of market access.
A product that is difficult for community practices to purchase sustainably may ultimately move to other sites of care or experience slower adoption.
How a Specialty Healthcare GPO Fits Into Buy-and-Bill
A specialty healthcare GPO does not determine payer reimbursement and cannot guarantee that an individual medication will be financially favorable for every practice.
Its role is on the pharmaceutical purchasing and contract administration side of the equation.
For eligible gastroenterology practices and other non-acute infusion providers, an infusion GPO or specialty drug GPO may help provide clearer visibility into:
- Manufacturer contracts
- GPO pricing
- Specialty drug purchasing
- Contract eligibility
- Product programs
- Class of trade
- Specialty pharmaceutical distribution
- Member roster management
- Contract changes
That information can help practices understand their acquisition opportunities while evaluating reimbursement separately.
For pharmaceutical manufacturers, a pharmaceutical GPO can provide a structured way to establish programs across eligible community providers while maintaining better visibility into participation and utilization.
The value is in creating more clarity around one of the most important variables in buy-and-bill economics: what the provider actually pays to acquire the drug.
Understanding the Full Economics of In-Office GI Infusion
Buy-and-bill can give gastroenterology practices greater control over specialty drug purchasing, inventory, and treatment delivery, but that control comes with financial responsibility.
Practices purchase medication before reimbursement is received. They carry inventory risk. They need enough working capital to finance high-cost therapies. They must monitor GPO pricing, payer reimbursement, ASP changes, biosimilar formularies, claims, and collections while continuing to support the clinical infrastructure required for infusion.
The economics work best when pharmaceutical acquisition, reimbursement, patient volume, and operational costs remain aligned.
When those pieces separate, a medication that appears profitable on paper can quickly become difficult to administer sustainably.
AlignedCareGPO helps support the pharmaceutical purchasing side of that equation by connecting eligible specialty providers with manufacturer GPO contracts, contract pricing, specialty drug purchasing opportunities, and relevant programs across non-acute and alternative sites of care.
For GI practices navigating a more complicated infusion market, better visibility into both acquisition cost and reimbursement can help turn buy-and-bill from a financial unknown into a more manageable part of specialty care.
Related Articles
What Anti-Amyloid Therapies Mean for Neurology Infusion Operations
Anti-amyloid therapies are reshaping neurology infusion by requiring coordinated systems for patient selection, imaging, medication access, monitoring, purchasing, and caregiver communication well beyond the infusion itself.
IVIG and SCIG Market Trends Specialty Providers Should Watch
The immunoglobulin market is becoming more segmented as IVIG, conventional SCIG, and facilitated SCIG expand across different care settings, distribution channels, reimbursement models, and patient preferences.
How Site-of-Care Decisions Are Changing Immunoglobulin Therapy
As immunoglobulin therapy expands across physician offices, infusion centers, specialty pharmacies, and patients’ homes, providers must balance clinical suitability with payer requirements, purchasing pathways, and individual patient preferences.
Stay Informed.
Stay Better Aligned.
Explore how AlignedCareGPO helps create stronger alignment between manufacturers, members, specialty distribution, and program execution to drive greater value across specialty healthcare.